Post 2 2023
-
Researchers Report Positive Trial Results on Four Investigative Agents for Asthma, COPD, and PAH
Four highly anticipated trials were presented at the ATS 2023 International Conference. The trials included the TORREY Study of Seralutinib, the ENHANCE Trials of Nebulized Ensifentrine, the Phase 1b Study of SAR443765 in Mild-to-Moderate Asthma, and the BOREAS Study of Dupilumab in COPD Patients with Type 2 Inflammation. Robert P. Frantz, MD, summarized the findings…
-
Clinical Year in Review 3 Focuses on Asthma, Sarcoidosis, Sepsis, Sleep
The third session of the annual Clinical Year in Review explored the latest developments in asthma, sarcoidosis, sepsis, and sleep. Using Single Maintenance and Reliever Therapy recommendations for patients with asthma addresses issues of self-management and adherence often seen in this population, reported Vanessa Marie McDonald, PhD.
-
Final Clinical Year in Review Examines New Research in Lung Transplantation, Medical Education, Health Disparities, CF and non-CF Bronchiectasis
The final Clinical Year in Review session covered lung transplantation, medical education, health disparities, and cystic fibrosis/non-cystic fibrosis bronchiectasis. Race-based corrections in spirometry are not clinically derived, said Deepshikha Charan Ashana, MD, MBA, MS.
-
Panel Discusses Alternatives to Race-Specific Equations in Pulmonary Function Testing
Co-authors of “Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement” participated in a panel of experts to discuss the potential harms and benefits of race-specific reporting in PFTs and propose alternatives that better reflect the populations served. The shift from race-specific PFT equations to race-neutral, or indeed some other…